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Background: Multiple studies investigated the associations between serum uric acid and coronary heart disease
(CHD) risk. However, further investigations still remain to be carried out to determine whether there exists a causal
relationship between them. We aim to explore the associations between genetic variants in uric acid related loci of
SLC2A9 and ABCG2 and CHD risk in a Chinese population.
Results: A case–control study including 1,146 CHD cases and 1,146 controls was conducted. Association analysis
between two uric acid related variants (SNP rs11722228 in SLC2A9 and rs4148152 in ABCG2) and CHD risk was
performed by logistic regression model. Adjusted odds ratios (ORs) with 95% confidence intervals (CIs) were
calculated. Compared with subjects with A allele of rs4148152, those with G allele had a decreased CHD risk and
the association remained significant in a multivariate model. However, it altered to null when BMI was added into
the model. No significant association was observed between rs11722228 and CHD risk. The distribution of CHD risk
factors was not significantly different among different genotypes of both SNPs. Among subjects who did not
consume alcohol, the G allele of rs4148152 showed a moderate protective effect. However, no significant
interactions were observed between SNP by CHD risk factors on CHD risk.
Conclusions: There might be no association between the two uric acid related SNPs with CHD risk. Further studies
were warranted to validate these results.
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Coronary heart disease (CHD) is one of the leading
causes of morbidity and mortality throughout the world
[1]. The World Health Organization estimated that each
year more than 700,000 people die from CHD in China
with a substantial economic burden [2]. CHD is a multi-
factorial disease resulting from genetic, environmental
factors and their interaction [3]. Known risk factors
for CHD include obesity, smoking, diabetes, dislipidemia
and etc. [4-7].* Correspondence: hemeian@hotmail.com
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unless otherwise stated.Uric acid, as the end product of purine metabolism,
is a major cause of gout [8,9]. Studies indicated that uric
acid levels were associated with insulin resistance [10]
and metabolic syndromes [11]. In addition, epidemiolo-
gical studies have investigated the association of uric
acid levels with CHD risk with inconsistent results
[4,12-19]. Some studies found uric acid levels were posi-
tively associated with CHD risk [4,13,14,20]. In contrast,
some studies found no association between them [21,22].
Similar controversial findings were found in Chinese
population [23-25]. Therefore, it still remains to be inves-
tigated whether there is a causal association between
serum uric acid levels and CHD risk.
Recent genome-wide association studies (GWASs) iden-
tified multiple genetic loci associated with serum uric acid
concentrations [9,13,18,26,27]. Our previous GWAS alsois is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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family 2, facilitated glucose transporter member 9, 4p16.1)
[18,22,26,28,29] and ABCG2 (ATP-binding cassette, sub-
family G, member 2, 4q22) [12,30,31] positively associated
with serum uric acid levels in a Chinese population [32].
Several studies investigated the associations between the
genetic variants in the uric acid related loci of SLC2A9
and ABCG2 and the risk of CHD among Europeans
[12,22,25,33,34] and found no association between them.
It is necessary to further investigate their associations
among other populations.
In the present study, a case–control design (consisting
of 1,146 cases with 1,146 age- and sex- frequency matched
controls) was adopted and two SNPs rs11722228 (intron
in SLC2A9) and rs4148152 (intron in ABCG2), which were
in the previously reported uric acid related loci and con-
firmed in our GWAS [32,35,36], were selected to examine
their associations with the CHD risk among Chinese. To
our best knowledge, there were no studies investigating
the association of these two SNPs and CHD risk before.
The results in the present study will help us to verify the
existence of causal relationship between serum uric acid
levels and CHD risk.
Methods
Study population
The subjects included in the present study were recruited
consecutively at the department of cardiology from three
hospitals (Tongji Hospital, Union Hospital, and Wugang
Hospital) in Wuhan city (Hubei province, China) between
May 2004 and October 2006. Quantitative coronaryTable 1 Baseline characteristics of the CHD case and control s
Variables CHD cases (n = 1,146)
Age (years) 60.0 ± 10.3
Gender (male/female) 891/255 (77.7/22.3)
BMI (kg/m2) 24.4 ± 3.3
Smoking, no/yes, (%) 774/369 (66.7/32.3)
Drinking, no/yes, (%) 822/317 (72.2/27.8)
Systolic blood pressure (mmHg) 136.0 ± 25.3
Diastolic blood pressure (mmHg) 82.9 ± 15.2
Fasting blood glucose (mmol/L) 6.2 ± 3.0
Total cholesterol (mmol/L) 4.4 ± 1.1
Triglyceride (mmol/L) 1.7 ± 1.4
HDL cholesterol (mmol/L) 1.2 ± 0.7
LDL cholesterol (mmol/L) 2.6 ± 0.9
Past history
Diabetes, no/yes, (%) 824/314 (72.4/27.6)
Hypertension, no/yes, (%) 351/790 (30.8/69.2)
Family history of CHD, no/yes, (%) 947/158 (85.7/14.3)
Values are mean ± SD, n (%) or as indicated. CHD: coronary heart disease; BMI: bodyangiography was performed by experienced cardiologists
who had no knowledge of the patients’ clinical informa-
tion. After exclusion of those who had acute renal and
liver diseases or with incomplete information, 2,292 indi-
viduals of 1,146 cases with 1,146 age- and sex- frequency
matched controls were included in our study. All the sub-
jects were unrelated Chinese Han individuals and lived in
Hubei province, the central China. The baseline charac-
teristics of cases and controls were shown in Table 1. Our
study has been approved by the Medical Ethics Commit-
tee of the School of Public Health, Tongji Medical College.
Written informed consents were obtained from all the
participants.
Data collection
General health examination was performed including
standing height and body weight. Height was measured
to the nearest 0.01 cm with subjects standing without
shoes. Weight was measured using a digital scale with
subjects wearing light clothing and recorded to the near-
est 0.1 kg. Body mass index (BMI) was calculated as
body weight in kilograms divided by standing height in
meters squared [7,37]. Those who had smoked more
than 100 cigarettes in lifetime were defined as smokers;
otherwise, they were defined as nonsmokers. Subjects
were considered hypertensive as blood pressure ≥140/
90 mmHg or they were treated with antihypertensive
medications. Diabetes mellitus was defined either by the
World Health Organization criteria or by self-report of
being previously diagnosed as diabetes [38]. Family his-
tory was positive if first-degree relatives had CHD [39].ubjects
Control subjects (n = 1,146) P value
60.5 ± 11.3 0.229
901/245 (78.6/21.4) 0.613
23.7 ± 3.1 <0.01
686/460 (59.9/40.1) <0.01
776/365 (68.0/32.0) <0.01
133.6 ± 29.0 0.034
82.0 ± 11.3 0.110
5.6 ± 2.2 <0.01
4.7 ± 0.9 <0.01
1.6 ± 1.3 0.283
1.1 ± 0.4 <0.01
2.7 ± 0.8 <0.01
1080/65 (94.3/5.7) <0. 01
784/361 (68.5/31.5) <0. 01
1133/10 (99.1/0.9) <0.01
mass index; HDL: high density lipoprotein; LDL: low density lipoprotein.
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cholesterol, and triglyceride levels were assayed according
to standard laboratory procedures in the Department of
Clinical Laboratory at Union Hospital and Tongji Medical
College.
Definition of coronary heart disease
The diagnostic criteria for CHD cases included one of
the followings: (1) presence of a stenosis > 50% in at least
one of the major segments of coronary arteries (right
coronary artery, left circumflex, or left anterior descend-
ing arteries) based on coronary angiography, which can
be seen in more details in previous studies [6,40,41]; (2)
according to the World Health Organization criteria in
terms of elevated cardiac enzymes, changes in electro-
cardiography and clinical symptoms; (3) a documented
history of coronary artery bypass graft or percutaneous
coronary intervention. Patients with congenital heart
disease, cardiomyopathy, or severe vascular disease were
excluded. All control subjects were determined to be
free of CHD and peripheral atherosclerotic arterial dis-
eases according to medical history, clinical examinations
and electrocardiography. The controls were recruited in
a population-based survey and resided in the same com-
munities as the cases.
Genotyping
Venous blood samples were collected after a 12 h over-
night fasting and were drawn within 2 vacuum (ethyl-
enediamine tetraacetic acid, EDTA) anticoagulation
tubes for plasma and DNA. The blood specimens were
frozen in −80°C until assayed. Genomic DNA was isolated
with a Puregene kit (Gentra Systems, Inc., Minneapolis,
MN, USA).
Two SNPs rs11722228 (SLC2A9) and rs4148152
(ABCG2), which were associated with uric acid levels in
our recent GWAS [32], were selected and genotyped with
the Sequenom MassARRAY iPLEX platform (Sequenom,
Inc. San Diego, CA, USA) in 384-well format. The call rate
was 97.6% and 97.1% for rs11722228 and rs4148152,
respectively. In addition, we re-genotyped 5% of the total
samples and the concordance is 100%. Both SNPs were
consistent with HWE (P > 0.05) except for a slight deviation
of rs4148152 in controls (P = 0.02) (data not shown).
Data analysis
Categorical variables were presented in percentages and
compared by Chi-square analysis. Continuous variables
were expressed in mean ± SD and compared by student’s
t-test or analysis of variation (ANOVA) unless otherwise
specified. We conducted logistic regression analysis to
calculate adjusted ORs and their 95% CIs for CHD risk
by different genotypes of these SNPs in the multivariate
models. Multivariate model 1 included age, sex, smoking,drinking, and family history of CHD. Multivariate model
2 included the same set of variables in model 1 plus
BMI. Based on the model 2, model 3 further included
total cholesterol, triglyceride, and the history of hyper-
tension and diabetes. Homozygous genotypes CC and
AA were used as reference genotypes for rs11722228
and rs4148152, respectively. The interactions between
the independent SNPs and the covariates such as age,
sex, BMI, smoking, and drinking were tested by introdu-
cing the SNP × environmental factor terms into the
multivariate logistical regression model. Simultaneously,
general linear model was performed and P for trend
was calculated to observe the distribution of several
traditional CHD risk factors among different genotypes
of both SNPs. A two-side P value of < 0.05 was consid-
ered statistically significant. All statistical analyses were
performed by the statistical analysis software package
SPSS 12.0.
Results
Baseline characteristics analysis between cases and
controls
In the present case–control study, CHD controls (n =
1,146) were frequency matched for age and sex to cases
(n = 1,146). Baseline characteristics of study individuals
are shown in Table 1. Compared with the control group,
CHD cases were more likely to have significantly higher
BMI, systolic blood pressure, fasting glucose, and HDL
cholesterol levels (all P < 0.05). However, the levels of
TC and LDL cholesterol were significantly lower in cases
than those in controls, which might be due to the intake
of cholesterol-lowering medications in CHD cases. The
percentage of past history of diabetes and hypertension,
and family history of CHD in cases were dramatic-
ally higher in contrast to that in control subjects (all
P < 0.01).
Associations of uric acid levels related SNPs with CHD risk
As shown in Table 2, the CC, CT, and TT genotype fre-
quency of SNP rs11722228 in controls was 52.7%, 40.3%,
and 7.0%. It was 50.2%, 42.0%, and 7.8% in the CHD
group, respectively. The frequency of the C and T allele
was not significantly different between the CHD group
and the control group. For the SNP rs4148152, the
genotype frequency of AA, AG, and GG in the controls
was 42.0%, 48.1%, and 9.9%. In cases it was 47.4%,
42.6%, and 10.0%, respectively. No significant difference
of the genotype frequency of rs4148152 was observed
between the CHD group and the control group. SNP
rs11722228 was not significantly associated with CHD
risk. In contrast, the rs4148152-AG genotype had a sig-
nificantly decreased risk of CHD (age and sex adjusted
OR = 0.78, 95% CI: 0.66-0.93; P = 0.006) and the associ-
ation stayed significant in a multivariate model (adjusted
Table 2 Adjusted Odds Ratios and 95% Confidence Intervals for CHD risk by different genotypes of the uric acid
















rs11722228 CC 564(50.2) 586(52.7) 1.00 - 1.00 - 1.00 - 1.00 -
SLC2A9 CT 472(42.0) 449(40.3) 1.09(0.92-1.30) 0.319 1.14(0.95-1.37) 0.175 1.08(0.89-1.31) 0.445 1.06(0.85-1.32) 0.611
4p16.1 TT 87(7.8) 78(7.0) 1.16(0.83-1.60) 0.388 1.19(0.84-1.69) 0.322 1.05(0.73-1.51) 0.801 1.27(0.84-1.93) 0.262
CT+TT 559(49.8) 527(47.3) 1.10(0.93-1.30) 0.268 1.15(0.96-1.37) 0.135 1.07(0.89-1.29) 0.452 1.09(0.88-1.35) 0.433
rs4148152 AA 533(47.4) 463(42.0) 1.00 - 1.00 - 1.00 - 1.00 -
ABCG2 AG 479(42.6) 530(48.1) 0.78(0.66-0.93) 0.006 0.80(0.66-0.97) 0.019 0.85(0.70-1.03) 0.088 0.92(0.74-1.16) 0.483
4q22 GG 112(10.0) 109(9.9) 0.89(0.67-1.20) 0.445 0.81(0.59-1.11) 0.192 0.81(0.58-1.12) 0.200 0.77(0.53-1.13) 0.182
AG+GG 591(52.6) 639(58.0) 0.80(0.68-0.95) 0.010 0.80(0.67-0.96) 0.015 0.84(0.70-1.01) 0.062 0.89(0.72-1.11) 0.306
a, adjusted for age (continuous), sex (male, female), smoking (yes/no), drinking (yes/no) and family history of CHD (yes/no).
b, adjusted for the same set of variables in model 1 plus BMI (continuous).
c, adjusted for the same set of variables in model 2 plus total cholesterol (continuous), triglyceride (continuous), and the history of hypertension and diabetes (yes/no).
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age, sex, smoking, drinking and family history of CHD
(model 1). However, the association altered to null when
BMI was introduced into the model (model 2). Subjects
carried the G allele of rs4148152 had a decreased risk of
CHD (AG +GG) (age and sex adjusted OR = 0.80, 95%
CI: 0.68-0.95; P = 0.010). The results remained significant
in model 1 (adjusted OR = 0.80, 95% CI: 0.67-0.96; P =
0.015) but changed to borderline significant in model 2
when BMI was introduced into the model (P = 0.062).
Further adjustment for the remaining traditional risk
factors including total cholesterol, triglyceride, and past
history of hypertension and diabetes got the similar null
results (P = 0.306).Table 3 Stratified associations of SNPs rs11722228 and rs414
rs11722228 ORs (95% CIs)
Variables CC CT TT CT+TT
Sex
Male 1.00 1.07(0.86-1.33) 1.14(0.75-1.71) 1.08(0.87-1.33)
Female 1.00 1.19(0.78-1.81) 0.77(0.34-1.75) 1.12(0.75-1.68)
BMI (kg/m2)
<24 1.00 0.97(0.74-1.27) 1.14(0.68-1.91) 1.00(0.77-1.29)
≥24 1.00 1.22(0.92-1.60) 1.01(0.61-1.68) 1.18(0.91-1.54)
Smoking
Yes 1.00 1.16(0.91-1.49) 1.23(0.77-1.97) 1.17(0.92-1.49)
No 1.00 1.01(0.74-1.37) 0.85(0.48-1.53) 0.98(0.73-1.32)
Drinking
Yes 1.00 0.88(0.62-1.26) 0.94(0.47-1.88) 0.89(0.64-1.25)
No 1.00 1.19(0.94-1.50) 1.09(0.71-1.67) 1.17(0.94-1.47)
ORs and 95% CIs were obtained from logistic regression analyses with adjustment f
stratified factor.
a, OR is significant at the 0.05 level.
P, for interactions of CHD traditional risk factors with rs11722228 and rs4148152.Interactions between uric acid levels related SNPs and the
traditional factors on CHD risk
We further investigated the associations between these
two SNPs and CHD risk stratified by several traditional
CHD risk factors such as sex (male/female), BMI (<24
and ≥24 kg/m2), smoking status (yes/no), alcohol con-
sumption status (yes/no). Table 3 shows the ORs with
95% CIs adjusting for other risk factors except for the
stratified factor. Among subjects who did not consume
alcohol, the G allele of rs4148152 showed a moderate
protective effect (adjusted OR = 0.79, 95% CI: 0.63-0.99;
P = 0.038), however, no significant interactions were
observed between alcohol consumption and SNP of
rs4148152 on CHD risk (P for interaction = 0.47). Similarly,8152 with CHD risk by CHD traditional risk factors
P rs4148152 ORs (95% CIs)
P AA AG GG AG+GG P
0.62 1.00 0.83(0.67-1.03) 0.83(0.58-1.21) 0.83(0.67-1.02) 0.86
1.00 0.82(0.54-1.26) 0.71(0.34-1.46) 0.80(0.53-1.20)
0.55 1.00 0.82(0.62-1.07) 0.84(0.54-1.32) 0.82(0.64-1.07) 0.99
1.00 0.86(0.65-1.14) 0.76(0.48-1.22) 0.84(0.65-1.10)
0.23 1.00 0.82(0.64-1.06) 0.78(0.51-1.19) 0.82(0.64-1.04) 0.77
1.00 0.87(0.64-1.19) 0.86(0.51-1.45) 0.87(0.65-1.17)
0.35 1.00 1.00(0.71-1.43) 0.82(0.42-1.56) 0.97(0.69-1.37) 0.47
1.00 0.79(0.63-1.00) 0.78(0.53-1.14) 0.79(0.63-0.99)a
or age, sex, BMI, smoking, drinking and family history of CHD except for the
Han et al. BMC Genetics  (2015) 16:4 Page 5 of 7no interactions were observed for the two SNPs and other
covariates on CHD risk.
The distribution of the traditional factors among different
genotypes of rs11722228 and rs4148152 in controls
We also examined the distribution of CHD traditional
risk factors including BMI, blood pressure, fasting blood
glucose, TC, TG, HDL cholesterol and LDL cholesterol
among different genotypes of SNPs rs11722228 and
rs4148152 in controls. As Additional file 1: Table S1
demonstrates, none of these factors showed statistically
significant differences among different genotypes of either
SNP.
Discussion
It still remains to be determined whether serum uric
acid is an independent risk factor of CHD risk. As Men-
delian randomization indicates, genetic variants could
serve as an instrument to explore the causal associations
between the biomarkers and the risk of diseases [13,42].
In the present study, we conducted a case–control study
and selected two uric acid related SNPs rs11722228 (SLC2A9)
[18,22,26,28,29] and rs4148152 (ABCG2) [12,30,31], which
were found in our previous GWAS [32], to explore the
potential contributing association of serum uric acid levels
and CHD risk in a Chinese population. However, no asso-
ciation was found between the two uric acid related SNPs
with CHD risk, indicating that there might not be causal
association between them. Further studies are warranted
to validate these results.
Previous GWASs have identified SLC2A9 and ABCG2
loci to be positively associated with serum uric acid
levels and gout [13,22,43]. SLC2A9, also known as
GLUT9 (glucose transporter type 9), is a glucose trans-
porter and plays a significant role in maintaining glucose
homeostasis. SLC2A9 is a causative gene for renal hyper-
uricemia and plays a significant role in urate reabsorp-
tion on renal proximal tubular cells [22,26]. ABCG2 is
one of adenosine triphosphate (ATP) binding cassette
family and expressed in kidney proximal tubule cellular
membrane [8,44]. It transports purine nucleoside ana-
logues, which resemble the molecular structure of uric acid
and mediates urate excretion in the kidney.
Unfortunately, we did not find significant associations
between the two variants and CHD risk. In addition,
considering that the CHD traditional risk factors might
modify these associations, we conducted stratification
and interaction analysis but no significant interactions
were found between these covariates and the two variants
on CHD risk. The results indicated that the associations
of the uric acid related variants with CHD risk were not
modified by these CHD traditional risk factors and there
might be no causal association between serum uric acid
levels and CHD risk.Several issues contributing to this null result should be
noted. Firstly, only two independent uric acid related
variants SNPs of rs11722228 and rs4148152 were selec-
ted to perform this association study and they explained
only 1.03% and 1.09% of the total variation of serum uric
acid levels, respectively [32]. Selection of more variants
that explained more percentage of uric acid levels was
warranted in further studies. Secondly, relatively small
sample size in the present case–control study provided
relatively weak power to examine this association. For
example, our study had more than 80% power to examine
variants with MAF = 0.3 and OR = 1.2 at two-side P < 0.05.
However, the present study only had 32% power to detect
variants with MAF = 0.3 and OR = 1.1 at P < 0.05 signifi-
cant level. Further studies with larger sample size were
needed to validate our results. Thirdly, the present study
was conducted in Chinese Han population, further studies
conducted in other populations were necessary.
Conclusions
In summary, this study did not find significant associ-
ation of uric acid related SNP rs11722228 in SLC2A9
with the risk of CHD in a Chinese population. Subjects
carried the G allele of rs4148152 in ABCG2 locus had
decreased CHD risk, however, this association altered to
borderline significant when BMI and other traditional
risk factors were introduced into the multivariable
model. No significant interactions between the two SNPs
and CHD related risk factors were observed. Studies
with larger sample size in other populations and genotyping
more variants related to uric acid levels were warranted in
future studies.
Additional file
Additional file 1: Table S1. The distribution of the covariates among
different genotypes of rs11722228 and rs4148152 in controls.
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